Clinical trials: Addiction, Drug
Depression, Dual Diagnosis
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
Methamphetamine (MA) addiction is a public health concern that causes substantial harm to individual users, and imposes an economic burden in the U.S. totaling up to $48.3 billion annually.
- Conditions
- Depression, Dual Diagnosis, Drug Addiction
- Trial name
- NCT02192931
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Perry Renshaw
Opioid Use Disorder (OUD)
HEALing Communities Study
This study will test the impact of implementing the Communities That Helping to End Addiction Long-term (HEAL) intervention on opioid overdose deaths within 67 highly affected communities with the goal of reducing opioid overdose…
- Trial name
- NCT04111939
- Testing
- Communities That HEAL, Wait-list control
- Where
- 4 sites in United States
- Volunteers
- 67 people
- Sponsor
- RTI International
Opiate Addiction, Refractory Pain
Buprenorphine as a Treatment in Opiate Dependent Pain Patients
This study is designed to determine if different doses of buprenorphine (either tapering doses or steady doses) are effective in managing chronic, non-cancer pain in individuals who also are addicted to opiate pain medicines.
- Trial name
- NCT00552578
- Testing
- buprenorphine/naloxone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- State University of New York at Buffalo
Drug Dependence
Improving Treatment Outcomes for Prescription Opioid Dependence
Overall, this proposal seeks to improve treatment strategies for the significant public health problem of prescription opioid dependence by determining whether gabapentin, a non-narcotic pharmaceutical agent with minimal abuse…
- Trial name
- GBN (NCT02543944)
- Testing
- Gabapentin, Buprenorphine, Clonidine
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Arkansas
Drug Dependence
Oxytocin and Cognitive Behavioral Therapy in Drug Dependence
Background: The therapeutic alliance between therapist and patient may contribute to favorable outcomes in all types of psychotherapy, including cognitive behavioral therapy (CBT) for drug dependence.
- Trial name
- NCT00975416
- Testing
- Cognitive Behavioral Therapy, Intranasal Oxytocin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Use Disorder, Pregnancy Related
Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD
The primary objective of this study is to evaluate the ability of TOME to increase Medication for Opioid Use Disorder (MOUD) and opioid-overdose knowledge in pregnant and postpartum persons.
- Conditions
- Opioid Use Disorder, Pregnancy Related, Substance Use, Drug Abuse
- Trial name
- TOME (NCT06262347)
- Testing
- Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME), Control
- Where
- 6 sites in United States
- Volunteers
- 131 people
- Sponsor
- T. John Winhusen, PhD
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Cocaine-related Disorder
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
This study assessed whether AFQ056 had a beneficial effect by reducing cocaine use in Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.
- Trial name
- NCT03242928
- Testing
- AFQ056
- Where
- 8 sites in Argentina, Spain and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc
Methamphetamine Dependence
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Modafinil is a non-amphetamine type stimulant that acts as a wakefulness-promoting drug, and is approved for managing symptoms of narcolepsy (i.e., daytime somnolence).
- Trial name
- Modafinil (NCT00469508)
- Testing
- Modafinil
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles